Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

LA Jolla Pharma (LJPC)

LA Jolla Pharma (LJPC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,108
  • Shares Outstanding, K 24,937
  • Annual Sales, $ 75,720 K
  • Annual Income, $ 19,660 K
  • 60-Month Beta 2.39
  • Price/Sales 2.05
  • Price/Cash Flow 7.95
  • Price/Book N/A
Trade LJPC with:
  • Price/Earnings ttm 51.83
  • Earnings Per Share ttm 0.15
  • Most Recent Earnings $0.08 on 08/15/22
  • Latest Earnings Date 08/18/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.04
  • Number of Estimates 1
  • High Estimate 0.04
  • Low Estimate 0.04
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.82 +6.87%
on 08/17/22
6.24 -0.32%
on 08/19/22
+0.03 (+0.48%)
since 07/19/22
3-Month
3.07 +102.61%
on 07/05/22
6.24 -0.32%
on 08/19/22
+2.16 (+53.20%)
since 05/19/22
52-Week
3.07 +102.61%
on 07/05/22
6.24 -0.32%
on 08/19/22
+2.56 (+69.95%)
since 08/19/21

Most Recent Stories

More News
Innoviva Completes Acquisition of La Jolla Pharmaceutical

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer...

INVA : 15.23 (-0.39%)
LJPC : 6.22 (unch)
MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MDWD : 14.31 (-5.23%)
LJPC : 6.22 (unch)
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 2.38% and 2.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

JAZZ : 120.41 (-0.08%)
LJPC : 6.22 (unch)
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SBTX : 5.87 (+1.03%)
LJPC : 6.22 (unch)
CNVY : 10.51 (-0.47%)
DRE : 48.20 (+0.48%)
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SBTX : 5.87 (+1.03%)
LJPC : 6.22 (unch)
CNVY : 10.51 (-0.47%)
DRE : 48.20 (+0.48%)
LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of La Jolla Pharmaceutical Company (NASDAQ: LJPC) to Innoviva, Inc. for $6.23 per share in cash is fair to La Jolla shareholders....

LJPC : 6.22 (unch)
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and...

INVA : 15.23 (-0.39%)
LJPC : 6.22 (unch)
RPRX : 30.38 (-0.23%)
SHAREHOLDER ALERT: Weiss Law Reminds LJPC, CNVY, ACC, and MN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

LJPC : 6.22 (unch)
CNVY : 10.51 (-0.47%)
ACC : 65.42 (+0.08%)
MN : 12.85 (+0.16%)
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, LJPC, FSI, SYRS

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RFP : 21.92 (-0.36%)
LJPC : 6.22 (unch)
FSI : 1.8900 (-0.53%)
SYRS : 5.36 (-8.22%)
SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical...

LJPC : 6.22 (unch)
INVA : 15.23 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 6.28
2nd Resistance Point 6.26
1st Resistance Point 6.24
Last Price 6.22
1st Support Level 6.20
2nd Support Level 6.18
3rd Support Level 6.16

See More

52-Week High 6.24
Last Price 6.22
Fibonacci 61.8% 5.03
Fibonacci 50% 4.65
Fibonacci 38.2% 4.28
52-Week Low 3.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar